Format

Send to:

Choose Destination
See comment in PubMed Commons below
Semin Oncol. 2013 Aug;40(4):436-43. doi: 10.1053/j.seminoncol.2013.05.013.

Systemic treatment options for untreated patients with metastatic clear cell renal cancer.

Author information

  • 1Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. molinaa@mskcc.org

Abstract

The introduction of therapy targeting vascular endothelial growth factor (VEGF) and the mammalian target of rapomycin (mTOR) has significantly improved the outcome of patients with metastatic renal cancer. In this article a comprehensive overview of treatment choices for previously untreated patients with metastatic disease is given. Both established and emerging therapeutic options are discussed, as are prognostic factors predicting outcome.

Copyright © 2013 Elsevier Inc. All rights reserved.

PMID:
23972707
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk